Twice‐a‐day PPI, tetracycline, metronidazole quadruple therapy with Pylera® or L a ctobacillus reuteri for treatment naïve or for retreatment of Helicobacter pylori . Two randomized pilot studies

Meta‐analysis of three‐in‐one single capsule bismuth‐containing quadruple therapy for the eradication of Helicobacter pylori

(2019) Olga P. Nyssen et al.   HELICOBACTER

Understanding treatment guidelines with bismuth and non-bismuth quadruple Helicobacter pylori eradication therapies

(2018) David Y. Graham et al.   Expert Review of Anti-Infective Therapy

Illusions regardingHelicobacter pyloriclinical trials and treatment guidelines

(2017) David Y Graham   GUT

Rifabutin Containing Triple Therapy and Rifabutin with Bismuth Containing Quadruple Therapy for Third-Line Treatment ofHelicobacter pyloriInfection: Two Pilot Studies

(2016) Antonio Francesco Ciccaglione et al.   HELICOBACTER

Inclusion of Lactobacillus Reuteri in the Treatment of Helicobacter pylori in Sardinian Patients

(2016) Maria P. Dore et al.   MEDICINE

How to Effectively Use Bismuth Quadruple Therapy

(2015) David Y. Graham et al.   GASTROENTEROLOGY CLINICS OF NORTH AMERICA

Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy

(2013) L. Gatta et al.   BMJ-British Medical Journal

Helicobacter pyloriresistance to antibiotics in Europe and its relationship to antibiotic consumption

(2012) Francis Megraud et al.   GUT

Twice-a-Day Bismuth-Containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Trial of 10 and 14 Days

(2011) Maria Pina Dore et al.   HELICOBACTER

Is There a Benefit to Extending the Duration of Helicobacter pylori Sequential Therapy to 14 Days?

(2011) Ping I. Hsu et al.   HELICOBACTER

Efficient Identification and Evaluation of Effective Helicobacter pylori Therapies

(2008) David Y. Graham   Clinical Gastroenterology and Hepatology